Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Change in Receivables (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Change in Receivables for 10 consecutive years, with -$869000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Receivables rose 57.36% year-over-year to -$869000.0, compared with a TTM value of -$1.1 million through Sep 2025, down 277.13%, and an annual FY2024 reading of $1.5 million, up 234.06% over the prior year.
  • Change in Receivables was -$869000.0 for Q3 2025 at Spero Therapeutics, down from $1.8 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $3.5 million in Q1 2024 and bottomed at -$6.7 million in Q2 2021.
  • Average Change in Receivables over 5 years is -$215263.2, with a median of $38000.0 recorded in 2021.
  • The sharpest move saw Change in Receivables tumbled 1202.29% in 2023, then skyrocketed 733.22% in 2025.
  • Year by year, Change in Receivables stood at $38000.0 in 2021, then surged by 244.74% to $131000.0 in 2022, then crashed by 1202.29% to -$1.4 million in 2023, then skyrocketed by 126.94% to $389000.0 in 2024, then plummeted by 323.39% to -$869000.0 in 2025.
  • Business Quant data shows Change in Receivables for SPRO at -$869000.0 in Q3 2025, $1.8 million in Q2 2025, and -$2.4 million in Q1 2025.